Friday is the last day to apply for help through Elevate Florida program
TREASURE ISLAND, Fla. (WFLA) — April 11 is the last day people can apply for assistance through the Elevate Florida program.
The program helps homeowners raise, rebuild, or strengthen their homes to help reduce damaged caused by storms.
Sarasota mother of children killed in hit-and-run dies months after crash
It is important to double check your information on the application, which many have told 8 On Your Side, is a confusing process.
To elevate your home or knock it down, Friday is the last day for homeowners to make the decision if they want to apply for the state's Elevate Florida program.
A decision that needs to be made soon, since hurricane season is now less than two months away.
'You won't be able to rebuild anything new that isn't elevated. It must be elevated,' said Derek Brunney, a homeowner in Pinellas County.
Eligible projects include structure elevation, mitigation reconstruction, and wind mitigation.
Homeowners are encouraged to double check their applications before submitting. While information sessions were held last month, many people walked away confused.
'It was information that already we've been able to get through the website on the application process,' said one resident.
'I was expecting a Q&A session rather than just reading from the documents that are already available,' said another resident who went to an information meeting.
To apply, you have to be at least 18, a U.S. citizen, and own your property.
The program could cover at least 75% of the cost to raise the home, as long as the homeowner can cover the rest.
Some are worried that they $400 million allocation from the state may not be enough to help everyone in need.
$220,000 each home that they're looking at allowing, that doesn't equal a whole lot of homes, and if that funding goes away, who is going to step in?' Brunney said.
The program is designed to protect homes and communities from natural disasters, like hurricanes.
If you still need to apply, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
DocuSign, Inc. (DOCU): A Bear Case Theory
We came across a bearish thesis on DocuSign, Inc. (DOCU) on Deep Value Returns' Substack. In this article, we will summarize the bears' thesis on DOCU. DocuSign, Inc. (DOCU)'s share was trading at $75.28 as of 6th June. DOCU's trailing and forward P/E were 14.31 and 20.07 respectively according to Yahoo Finance. A close-up of a laptop displaying loan documents, representing the company's residential mortgage guaranty insurance and mortgage loans. DocuSign (DOCU) saw its stock fall nearly 17% to around $77 following a disappointing fiscal 2026 outlook, which revised expected billings growth from 9% to 7% year-over-year. This was a significant setback for what had been a slow turnaround story, with billings being a key leading indicator of future revenue. The updated guidance casts doubt on the company's ability to reaccelerate growth, suggesting revenue may trend from 8% to as low as 5% y/y through the remainder of the year. Compounding concerns, DocuSign's free cash flow margins—a core pillar of the bull thesis—fell to 29.8% in Q1 from 32.7% a year earlier, prompting a downward revision of full-year margin expectations from 33% to 31%. While DocuSign still boasts a strong balance sheet with no debt and roughly $950 million in cash (about 6% of its market cap), the business is now expected to generate just $985 million in free cash flow, implying a 16x forward multiple for a company facing marginal growth. This valuation is no longer attractive in light of eroding operating leverage. The author, previously optimistic due to the company's margin potential and balance sheet strength, now views the risk/reward as balanced at best. With both billings and free cash flow coming in below even conservative expectations, the original thesis has broken down. As such, the author's position has been closed, with capital redirected toward opportunities offering stronger growth visibility and cleaner execution setups. This candid reassessment reflects a disciplined exit rather than emotional capitulation. Previously, we summarized a standout on Super Micro Computer by the same author, emphasizing its strategic alignment with AI infrastructure demand, scalable custom server offerings, and attractive free cash flow valuation, arguing that current headwinds are transitory and already priced in. DocuSign, Inc. (DOCU) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held DOCU at the end of the first quarter which was 51 in the previous quarter. While we acknowledge the risk and potential of DOCU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025
Collaboration addresses interactive solutions for smart glasses as global smart glasses shipments surge 210%i year-over-year LONG BEACH, Calif., June 10, 2025--(BUSINESS WIRE)--KiWear, Inc. today announced a reference design for a smart ring input solution for use with smart glasses and AI glasses during Qualcomm Technologies, Inc.'s opening keynote presentation at AWE USA 2025. The collaboration aims to help OEMs develop interactive solutions for AI smart glass partners. Industry analysts expect 60% year-over-year growth in 2025 and a sustained CAGR of over 60% through 2029. "Qualcomm Technologies is fueling the AI glasses industry with our Snapdragon® XR Platforms. KiWear's smart ring, featuring algorithms co-developed with Qualcomm Technologies, makes an ideal input device for smart glasses and AI glasses," said Ziad Asghar, SVP & GM of XR at Qualcomm Technologies, Inc. "This new reference design represents a step forward in helping OEMs to deliver solutions that enable intuitive and discreet gesture based interaction for the growing category of AI smart glasses. "We are thrilled to build next generation input solutions for both AI and XR together with industry leaders such as Qualcomm," said Chris Shi, Founder and CEO of KiWear, Inc. Leading HCI Innovation KiWear, recognized as a leader in HCI innovations, has developed cutting-edge smart ring technology that enables seamless hand-centric interactions with smart glasses and AI glasses. The company's solutions address fundamental input challenges that have limited widespread smart glasses adoption. Founded in April 2025, KiWear is a Delaware-based company delivering comprehensive HCI solutions for multi-DoF controllers, smart rings, and wearables. The company brings together prominent computer vision scientists, AI/XR integration experts, and hardware/software innovators, with expertise spanning conceptualization to mass production. KiWear has forged collaborations and delivers exclusive solutions to six of the global top 10 consumer electronics leaders. With R&D hubs in Shanghai and Beijing beyond its U.S. headquarters, the company partners with premier technology conglomerates to enable natural HCI solutions for next-generation XR and AI products. Live Demonstrations Conference attendees can experience KiWear's smart ring and watch technologies at the Qualcomm Technologies' booth (Booth 209) during AWE USA, showcasing seamless integration with smart glasses platforms. Snapdragon is a trademark or registered trademark of Qualcomm Incorporated. Snapdragon branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. __________________________ i Source: View source version on Contacts Media Contact:Sally GaoKiWear +86-13918187350
